Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Lyra therapeutics (NASDAQ: LYRA ) is developing corticosteroid-eluting implants for treatment of chronic rhinosinusitis; LYR-210 for patients without prior surgery and LYR-220 for patients with prior ethmoid sinus surgery. A single therapy (easily placed at the ENT's office) providesAnalyst’s Disclosure:I/we have a beneficial long position in the shares of LYRA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving com ...